Category: Pharmaceuticals and Biotech

Latest Biologic Launch in Psoriasis, UCB's Cimzia, Having a Tough Time Getting Traction, But Developing a Presence in Dermatology May Lay Foundation for Bimekizumab in the Future
Press Release -

Latest Biologic Launch in Psoriasis, UCB's Cimzia, Having a Tough Time Getting Traction, But Developing a Presence in Dermatology May Lay Foundation for Bimekizumab in the Future

Janssen's Tremfya continues to post gains, but may soon face competition as Sun Dermatology readies for the launch of Ilumya (tildrakizumab), the second IL-23 inhibitor to be introduced in the U.S. market, according to a new report from Spherix Global Insights

Primate Research Firm Explores Blockchain Technology
Press Release -

Primate Research Firm Explores Blockchain Technology

Alpha Genesis initiative with important medical research implications

Masy BioServices to Distribute New Products
Press Release -

Masy BioServices to Distribute New Products

Masy, a leading provider of quality solutions for Life Sciences, is now offering precision products from SenseAnywhere and Insatech

Longevity Biotech Initiates Clinical Neuroinflammation Biomarker Study at the Department of Veterans Affairs to Investigate Immune Related Aspects of Parkinson's Disease With Continued Support From the Michael J. Fox Foundation
Press Release -

Longevity Biotech Initiates Clinical Neuroinflammation Biomarker Study at the Department of Veterans Affairs to Investigate Immune Related Aspects of Parkinson's Disease With Continued Support From the Michael J. Fox Foundation

Study aims to identify novel blood-based inflammatory markers that can be used to both identify and stratify Parkinson's disease patients

Upcoming Xtalks Webinar: How the New FDA Drug-Drug Interaction Guidance Fits Within the Drug Development De-Risking Model
Press Release -

Upcoming Xtalks Webinar: How the New FDA Drug-Drug Interaction Guidance Fits Within the Drug Development De-Risking Model

Pharmaceutical development is inherently risky. To develop a molecule that has a desired, efficacious, but safe, effect in humans is a remarkable achievement considering the statistics.

Cryogenic Supply Chain Risk Management During Storage and Transportation of Reproductive Material, New Webinar Hosted by Xtalks
Press Release -

Cryogenic Supply Chain Risk Management During Storage and Transportation of Reproductive Material, New Webinar Hosted by Xtalks

Earlier this year, two fertility clinics experienced liquid nitrogen tank failures and thousands of eggs and embryos were compromised. These two catastrophic incidents highlight the risks associated with the storage and transportation of human reproductive materials including sperm, eggs and embryos.

Continuous Growth in the Pharmaceutical Industry is Fueling the Growth of the Global Pharmaceutical Desiccant Market at 4.39% of CAGR by 2026
Press Release -

Continuous Growth in the Pharmaceutical Industry is Fueling the Growth of the Global Pharmaceutical Desiccant Market at 4.39% of CAGR by 2026

According to the new market research report launched by Inkwood Research, The Global Pharmaceutical Desiccant market was valued at nearly $127650 million in 2017 and is anticipated to reach around $188150 million by 2026, growing at an estimated CAGR of 4.39% during the forecast period 2018-2026.

Clinical Pipe Debuts Pharma's First EHR-to-EDC Integration App at DIA 2018
Press Release -

Clinical Pipe Debuts Pharma's First EHR-to-EDC Integration App at DIA 2018

Clinical Pipe allows patient data to be exported directly from a clinical site's EHR and transferred into clinical research EDC.

Anders Kristensson Appointed CEO of TikoMed
Press Release -

Anders Kristensson Appointed CEO of TikoMed

First Influenza-Specific Neuraminidase Test Kit
Press Release -

First Influenza-Specific Neuraminidase Test Kit

InDevR's VaxArray® vaccine potency testing platform now includes a reagent kit for rapid assessment of neuraminidase in influenza vaccines

Rising Prevalence of Genetic Disorders Upswings the Global Crispr Market to Grow at 36.53% of CAGR by 2026
Press Release -

Rising Prevalence of Genetic Disorders Upswings the Global Crispr Market to Grow at 36.53% of CAGR by 2026

According to the new market research report launched by Inkwood Research, The Global CRISPR Market was valued around $ 500 million in 2017 and is anticipated to reach 8000 million by 2026, growing at an estimated CAGR of 36.53%, during the forecast period 2018-2026.

Press Release -

ILB - a Game Changer in Glaucoma

Immunotherapy Trials: Overcoming the Challenges of Selecting the Correct Patient Population, New Webinar Hosted by Xtalks
Press Release -

Immunotherapy Trials: Overcoming the Challenges of Selecting the Correct Patient Population, New Webinar Hosted by Xtalks

One of America's foremost oncologists leads this webinar series on the past, the present and the future of immunotherapy studies

Dismantling Data Silos to Improve Study Startup and Mitigate Risk, New Webinar Hosted by Xtalks
Press Release -

Dismantling Data Silos to Improve Study Startup and Mitigate Risk, New Webinar Hosted by Xtalks

The focus on technology as a driver of performance improvement in clinical trials is intense, but despite years of valiant efforts, study execution remains far from optimal - for study startup, the data are dismal

Early Alzheimer's Disease: Finding the Right Patients for Clinical Trials and Beyond, New Webinar Hosted by Xtalks
Press Release -

Early Alzheimer's Disease: Finding the Right Patients for Clinical Trials and Beyond, New Webinar Hosted by Xtalks

Industry experts will tackle the challenge of recruiting patients with early stage Alzheimer's disease into clinical trials to expedite treatment development

Heavy Menstrual Bleeding: Medical Background and PI and Patient Perspectives on Clinical Trials, Webinar for National Women's Health Week Hosted by Xtalks
Press Release -

Heavy Menstrual Bleeding: Medical Background and PI and Patient Perspectives on Clinical Trials, Webinar for National Women's Health Week Hosted by Xtalks

This clinical trials-related webinar will provide background on heavy menstrual bleeding (HMB) and discuss HMB trials from the PI and patient perspectives